| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Stryker Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$365.57 |
| 52 Week High | US$373.90 |
| 52 Week Low | US$250.79 |
| Beta | 0.92 |
| 11 Month Change | 4.79% |
| 3 Month Change | 7.32% |
| 1 Year Change | 27.47% |
| 33 Year Change | 32.43% |
| 5 Year Change | 68.34% |
| Change since IPO | 334.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R2S | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -1.7% | -4.4% | -0.6% |
| 1Y | 27.5% | 4.9% | 5.4% |
Return vs Industry: 0R2S exceeded the UK Medical Equipment industry which returned 4.9% over the past year.
Return vs Market: 0R2S exceeded the UK Market which returned 5.4% over the past year.
Price Volatility
| 0R2S volatility | |
|---|---|
| 0R2S Average Weekly Movement | 2.6% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R2S has not had significant price volatility in the past 3 months.
Volatility Over Time: 0R2S's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 52,000 | Kevin Lobo | www.stryker.com |
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Stryker Corporation Fundamentals Summary
| 0R2S fundamental statistics | |
|---|---|
| Market cap | US$139.02b |
| Earnings (TTM) | US$3.45b |
| Revenue (TTM) | US$21.39b |
40.3x
P/E Ratio6.5x
P/S RatioIs 0R2S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R2S income statement (TTM) | |
|---|---|
| Revenue | US$21.39b |
| Cost of Revenue | US$7.70b |
| Gross Profit | US$13.69b |
| Other Expenses | US$10.24b |
| Earnings | US$3.45b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.05 |
| Gross Margin | 64.00% |
| Net Profit Margin | 16.12% |
| Debt/Equity Ratio | 61.8% |
How did 0R2S perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield35%
Payout RatioDoes 0R2S pay a reliable dividends?
See 0R2S dividend history and benchmarks| Stryker dividend dates | |
|---|---|
| Ex Dividend Date | Sep 30 2024 |
| Dividend Pay Date | Oct 31 2024 |
| Days until Ex dividend | 9 days |
| Days until Dividend pay date | 40 days |
Does 0R2S pay a reliable dividends?
See 0R2S dividend history and benchmarks